WO1996026941A1 - PYRIMIDO[4,5-b]INDOLES - Google Patents

PYRIMIDO[4,5-b]INDOLES Download PDF

Info

Publication number
WO1996026941A1
WO1996026941A1 PCT/US1996/002397 US9602397W WO9626941A1 WO 1996026941 A1 WO1996026941 A1 WO 1996026941A1 US 9602397 W US9602397 W US 9602397W WO 9626941 A1 WO9626941 A1 WO 9626941A1
Authority
WO
WIPO (PCT)
Prior art keywords
thru
defined above
optionally substituted
pyrimido
carbon
Prior art date
Application number
PCT/US1996/002397
Other languages
English (en)
Inventor
Gordon L. Bundy
John R. Palmer
Gregory L. Weber
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Priority to US08/875,466 priority Critical patent/US5795986A/en
Priority to AU51722/96A priority patent/AU694853B2/en
Priority to NZ304519A priority patent/NZ304519A/xx
Priority to EP96908500A priority patent/EP0812322A1/fr
Priority to JP8526336A priority patent/JPH11501623A/ja
Publication of WO1996026941A1 publication Critical patent/WO1996026941A1/fr
Priority to MXPA/A/1997/006632A priority patent/MXPA97006632A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) of the invention are useful as pharmaceutical agents for a number of different indications.
  • pyrimido[4,5-b]indoles (I) and the lactams (XIII) of the present invention are chemically structurally similar to pyrrolo[2,3-d]pyrimidines.
  • GB 1,268,772 discloses tricyclic compounds where the diaminosubstituted ring is not a pyrimidinyl ring system.
  • J. Heterocyclic. Chem., 25, 1633-39 (1988) discloses compounds which have various oxygenated groups attached to the six membered non-pyrimidinyl ring.
  • the compounds of the present invention do not have any oxygen functionality on the six member non-pyrimidinyl ring.
  • R 2-14 may be the same or different and is
  • R 2-14 may be the same or different and is as defined above, or R 2-1 and R 2-2 are taken together with the attached nitrogen atom to form a heterocyclic ring selected from the group consisting of
  • R 2-3 is selected from the group of (1) C 1 -C 6 alkyl optionally substituted with 1 thru 3 -OH or -OCH 3 ,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above and optionally substituted in the 4-position with R 2-5 where (1) C 1 -C 6 alkyl optionally substituted with 1 thru 3 -OH or -OCH 3 ,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 where R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 4-1 is defined the same as R 2-1 , but may be the same or different than R 2-1 ,
  • R 4-2 is defined the same as R 2-2 , but may be the same or different than R 2-2 ;
  • R 7-4 and R 7-5 are the same or different and are C 1 -C 4 alkyl or may taken together with the attached nitrogen atom to form the heterocyclic ring -N * -(CH 2 ) n1 -R 5-6 -(CH 2 ) n2 * where the atoms marked with an asterisk ( * ) are bonded together resulting in the formation of a ring, where n 1 is 1 thru 5, n 2 is 0 thru 3 and R 5-6 is
  • R 2-14 may be the same or different and is
  • R 2-14 may be the same or different and is as defined above, or R 2-1 and R 2-2 are taken together with the attached nitrogen atom to form a heterocyclic ring selected from the group consisting of
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above and optionally substituted in the 4-position with R 2-5 where (1) C 1 -C 6 alkyl optionally substituted with 1 thru 3 -OH or -OCH 3 ,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 where R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 2-3 is as defined above,
  • R 4-2 is defined the same as R 2-2 , but may be the same or different than R 2-2 ; and pharmaceutically acceptable salts thereof.
  • International Publication No. WO93/20078 discloses compounds which are bicyclic heterocyclic amines (XXX).
  • pyrimido[4,5-b]indoles (I) of the present invention are made by the general processes set forth in International Publication No. WO93/20078 and by means well known to those skilled in the art.
  • pyrimido[4,5-b]indoles is the halogenated (X 1 is -Cl or -Br) diaminopyrimidine (II). It is preferred that X 1 be -Cl.
  • the final desired amino substituents (-NR 2-1 R 2-2 and -NR 4-1 R 4-2 ) on the pyrimidine ring are added or formed.
  • the substituents -NR 2-1 R 2-2 and -NR 4-1 R 4-2 may be the same or different; it is preferred that they be the same for simplicity of chemical synthesis.
  • tertiary amines (-NR 2-1 R 2-2 , -NR 4- 1 R 4-2 ) from halogenated aromatic/heteroaromatic compounds is known to those skilled in the art, see J. Med. Chem., 33, 1145 (1990). Generally, after the desired amino groups at the C 2 and C 4 positions are formed, and the R 7 substituent is introduced, the 5-membered ring is formed.
  • the R 2-1 and R 2-2 are taken together with the attached nitrogen atom to form a heterocyclic ring.
  • the heterocyclic ring be selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-methylpiperazinyl, 4-thiomorpholinyl, 1-piperazinyl. It is more preferred that R 2-1 and R 2-2 form 1-pyrrolidinyl or 1-piperazinyl, it is even more preferred that R 2-1 and R 2-2 form 1-pyrrolidinyl.
  • R 4-1 and R 4-2 be cyclized to form the same rings as for R 2-1 and R 2-2 .
  • the heterocyclic rings formed by R 2-1 /R 2-2 , and R 4-1 /R 4-2 can be substituted with 1 thru 3 groups, R 2-3 .
  • R 2-3 is alkyl, no more than two such groups can be on any one carbon atom in the ring.
  • R 2-3 is other than alkyl, only one such group can be on any one carbon atom. It is well known how to prepare these groups, see for example US Patent 5,175,281 which discloses how to prepare numerous diaminosubstituted pyrimidines such as bis( 1- pyrrolidinyl)pyrimidine.
  • CHART A discloses a general process for transformation of the appropriate diaminopyrimidine (II) to the corresponding pyrimido[4,5-b]indoles (I), for all R 7 except where R 7 is -H.
  • CHART B discloses a more specific process for
  • CHART C discloses a specific process for transformation of the appropriate diaminopyrimidine (II) to the corresponding pyrimido[4,5-b]indoles (I), where R 7 is -H. It is preferred that R 7 is 2-(4-morpholinyl)ethyl, 2-(1-imidazolyl)ethyl and 2-(1-piperidinyl)ethyl; it is more preferred that R 7 is 2-(4-morpholinyl)ethyl.
  • diaminopyrimidine (II) where X 1 is a leaving groups such as -Br or -Cl or the equivalent thereof. It is preferred that X 1 is -Cl.
  • the diaminopyrimidine (II) is then converted to the corresponding triaminopyrimidine (III) by reaction with the appropriate R 7 -NH amine by means known to those skilled in the art. With inexpensive, readily available amines, this can be accomplished by simply dissolving the diaminopyrimidine (II) in an excess of the R 7 -N ⁇ 2 amine and heating.
  • the preformation of the anion R 7 -NH- with a strong base such as butyl lithium enhances the nucleophilicity of the amine sufficiently. If it is desired to use less of the R 7 -NH 2 amine, for whatever reason, a slight excess of the amine or its anion is all that is required and this can be heated in a solvent such as DMF, THF, xylene or the equivalent thereof. The addition of excess of a low molecular weight tertiary amine neutralizes the acid (hydrochloric) formed in the reaction.
  • a suitable amine is triethylamine.
  • the triaminopyrimidine (III) is then cyclized to form the corresponding saturated tricyclic compound (IV) by means known to those skilled in the art. This is accomplished by treatment of the triaminopyrimidine (III) with ⁇ -bromocyclohexanone ( ⁇ -chlorocyclohexanone is also operable) in the presence of an organic base such as triethylamine, diisopropylethylamine and the like in solvents such as THF, DMF, DMSO or acetonitrile. Acetonitrile is the preferred solvent.
  • ⁇ -bromocyclohexanone ⁇ -chlorocyclohexanone is also operable
  • an organic base such as triethylamine, diisopropylethylamine and the like
  • solvents such as THF, DMF, DMSO or acetonitrile.
  • Acetonitrile is the preferred solvent.
  • the necessary alkylation/cyclization/dehydration occurs
  • the saturated tricyclic compound (IV) is isolated by crystallization or chromatography or may be carried on without isolation. Last the saturated tricyclic compound (IV) is dehydrogenated by known means such as DDQ, chloranil, or heating with palladium-on-carbon catalysts in high boiling solvents such as decalin or diphenylether to produce the desired pyrimido[4,5-b]indoles (I).
  • the preferred compounds of the invention are those where R 7 is C 2 alkyl substituted with a cyclized amino group.
  • R 7 is C 2 alkyl substituted with a cyclized amino group.
  • These compounds are best prepared by the process of CHART B. The process is much the same as with CHART A except the amino group reacted with the diaminopyrimidine (II) starting material is hydroxyethylamine (NH 2 -CH 2 -CH 2 -OH) to form the hydroxyethyl diaminopyrimidine (VI). This material is cyclized to the corresponding hydroxyethyl saturated tricyclic compound (VII) and dehydrogenated to the corresponding hydroxyethyl unsaturated tricyclic compound (VIII) in the same way as previously described for CHART A.
  • the hydroxyl group is transformed to a good leaving group -X 2 .
  • This leaving group includes such items as halogen, sulfonate esters like methanesulfonate, and equivalent groups.
  • the leaving group X 2 is replaced by "R" where R 7 is -CH 2 -CH 2 -R to form a preferred pyrimido[4,5-b]indoles (la).
  • CHART C discloses how to make pyrimido[4,5-b]indoles (I), where R 7 is -H.
  • the amine which is reacted with the diaminopyrimidine (II) starting material is t-butylamine forming the triaminopyrimidine (III) where the new substituent is -NH-(t-butyl).
  • This .-butyl substituted triaminopyrimidine (III) is then cyclized and unsaturated as for the general process of CHART A to produce the t-butylsaturated tricyclic compound (XI) and the t-buty .unsaturated tricyclic compound (XII). Lastly, the t-butyl group is replaced by -H to produce the pyrimido[4,5-b]indoles (lb) by means known to those skilled in the art.
  • Typical conditions involve heating the t-butylunsaturated tricyclic compound (XII) in a acidic medium, preferably trifluoroacetic acid, or concentrated aqueous hydrogen bromide or concentrated aqueous hydrogen chloride, and the like.
  • a acidic medium preferably trifluoroacetic acid, or concentrated aqueous hydrogen bromide or concentrated aqueous hydrogen chloride, and the like.
  • trichloropyrimidine A mixture of the trihalopyrimidine in an inert solvent such as THF is allowed to react with 1 equivalent of a primary amine, R 7 -NH 2 in the presence of an acid scavenger.
  • Organic amines such as pyridine, triethylamine, di- isopropylethylamine and inorganic bases such as potassium carbonate are useful acid scavengers.
  • the reactants are mixed at a reduced temperature (-80° to 0°) and the reaction mixture is allowed to warm to room temperature (20-25°) and then is often concentrated at reduced pressure.
  • the residue is partitioned between an organic solvent such as ethyl acetate or methylene chloride and an aqueous inorganic base such as potassium bicarbonate.
  • the extract is dried, concentrated, and the residue chromatographed on silica gel to separate the desired 4-amino-pyrimidine.
  • the 4-aminopyrimidine is mixed with an excess of a secondary amine, NHR 2-1 R 2-2 and the mixture is heated under reflux for 2 to 24 hours. The mixture is allowed to cool and then is concentrated.
  • the residue is partitioned as described above to remove the inorganic salts.
  • the crude product is purified by conventional means (e.g. crystallization and/or chromatography) to give the desired trisubstituted pyrimidine.
  • reaction mixture is diluted with an organic solvent such as ethyl acetate and the mixture is washed with an aqueous inorganic base.
  • organic solvent such as ethyl acetate
  • R 7 substituent may be desirable to modify the R 7 substituent after it is added to the tricyclic ring system rather than add the R 7 group in final form.
  • the group may be a removable group such as tert-butyl or N-benzyl. Deprotection of such a compound by methods known to those skilled in the art will provide the -N-H analog. Alkylation, acylation, or other routine operations will provide compounds of formula (I) with a new R 7 .
  • the substituents at R 7 may contain a modifiable functional group that can produce new compounds containing altered R 7 substituents.
  • the amine groups (-NR 2 -1 R 2-2 , -NR 4-1 R 4-2 ) may contain modifiable functional groups (possibly in a protected form) which can be modified as described above to form compounds containing new
  • hydroxyethyl unsaturated tricyclic compound (VIII) all by chemistry which is known to those skilled in the art, see J. Heterocyclic Chem. 10, 249 (1973).
  • the free hydroxyl group of the hydroxyethyl unsaturated tricyclic compound (VIII) is converted to a good leaving group to form the hydroxyethyl unsaturated tricyclic compound with leaving group (IX) as is known to those skilled in the art.
  • the hydroxyethyl unsaturated tricyclic compound with leaving group (IX) is reacted with ethanolamine to form the alcohol (XIV).
  • the alcohol (XIV) is reacted with the dichloro compound, Cl-CH 2 -CO-Cl (XV) to form the chloroalcohol (XVI) as is known to those skilled in the art. Finally the chloroalcohol (XVI) is cyclized by known means to form the lactam (XIII).
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are amines, and as such form acid addition salts when reacted with acids of sufficient strength.
  • Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The pharmaceutically acceptable salts are preferred over the corresponding free amines since they produce compounds which are more water soluble and more crystalline.
  • acids hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, citric, methanesulfonic, CH 3 -(CH 2 ) n1 -COOH where n 1 is 0 thru 4, HOOC-(CH 2 )n 1 -COOH where n is as defined above, HOOC-CH CH-COOH, ⁇ -COOH.
  • pyrimido[4,5-b]indoles (I) and the lactams (XIII) salts form hydrates and solvates either with one molecule of water or solvent or partial or multiples thereof.
  • pyrimido[4,5-b]indoles (I) it means and includes the
  • the pyrimido[4,5-b]indole (I) and the lactams (XIII) be selected from the compounds of EXAMPLES 3, 5, 8, 10 and 30. It is more preferred that the pyrimido[4,5-b]indole (I) be the compound of EXAMPLE 10, more preferably the salt of EXAMPLES 12 and 14, still more preferably the salt of EXAMPLE 12.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating and/or preventing spinal injury mild and/or moderate to severe head injury, subarachnoid hemorrhage (SAH) and subsequent ischemic stroke, asthma and reduction of mucous formation/secretion in the lung, muscular dystrophy, adriamycin cardiac toxicity, Parkinsonism, other degenerative neurological disorders, multiple sclerosis, organ damage during reperfusion after transplant, preservation of transplant organs by treatment of the donor, skin graft rejection, hemorrhagic, traumatic and septic shock, and conditions such as severe burns, ARDS, chemical oxidant-induced injury to the kidney (for example, inhibition of contrast dye nephropathy and inhibition of cyclosporine toxicity) nephrotic syndrome (immunological), systemic lupus erythematosus, allergic reactions, atherosclerosis, inflammation (dermatological antiinflammatory and antipsoriasis agents
  • the compounds are also useful for prophylactic treatment before surgical procedures such as hip and jaw surgery where the pyrimido[4,5-b]indoles (I) reduces edema. They are useful for preventing neurologic injury during surgical procedures and neurological procedures, for treatment of myocardial infarctions, for treatment after resuscitation to improve outcome, particularly neurological outcome post
  • the compounds have use in ophthalmology, e.g., in treatment of diabetic retinopathy, age-related macular degeneration, cataracts and glaucoma, light-induced retinal damage and in irrigation mixtures used in eye surgery, prevention of hyperoxic injury in adults and infants, reduction of facial edema after surgical procedures such as oral/facial surgery or trauma from accidents.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) also can be co-administered with anti-cancer drugs such as adriamycin, taxol or vinblastine when the tumor or cell strain becomes resistant as the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are an effective inhibitor of multiple drug resistance.
  • anti-cancer drugs such as adriamycin, taxol or vinblastine when the tumor or cell strain becomes resistant
  • anti-cancer drugs such as adriamycin, taxol or vinblastine
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are also useful in protection from radiation injury, particularly in brain and gut.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) can be administered topically (e.g. by suppository) or by other more common routes. This is particularly helpful in preventing gut injury during prostate irradiation.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating subarachnoid hemorrhage and subsequent cerebral vasospasm, global cerebral ischemia post resuscitation (CPR) to prevent post-ischemic brain damage, brain tumor (neuroprotective), Bells Palsy, other degenerative neurological disorders, hepatic necrosis (e.g. from viral hepatitis), some forms of radiation damage (for example during radiation treatment or from accidental exposure to radiation), myocardial damage after myocardial ischemia, pre-birth infant strangulation and infant hypoxia syndrome, such ophthalmic disorders as uveitis and optic neuritis and ischemic bowel syndrome.
  • CPR global cerebral ischemia post resuscitation
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in preventing damage following cardiopulmonary resuscitation, neurological or cardiovascular surgery and from cardiac infarction, ocular damage after ophthalmic surgery (e.g. cataritic surgery).
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating complications of surgery or trauma such as edema and neurologic injury and renal injury.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are used like the glucocorticoid pharmaceuticals for the treatment of the above human conditions as well as the animal conditions listed below. While the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in both humans and animals in treating many of the same conditions and preventing complications and damage from the same problems as the glucocorticoids, the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating a number of conditions and preventing damage from
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) have no glucocorticoid activity and therefore, unlike the glucocorticoids, they can be given daily for longer periods of time without the side effects associated with the glucocorticoids. This is a distinct advantage. They have no effect on blood glucose and this is also an advantage.
  • the standard conditions for treatment are to give the pyrimido[4,5-b]indoles (I) and the lactams (XIII) orally or parenterally, e.g. IV (that is by injection, infusion or continuous drip) or IM, with a standard dose of about 5 to about 20 mg/kg/day IV for up to 20 days (with 10 days being sufficient for some conditions) or about 5 to about 30 mg/kg/day; one to four times daily by mouth.
  • Females may be given higher doses than males since, on the average, they metabolize the pyrimido[4,5-b]indoles (I) and the lactams (XIII) more rapidly than males.
  • the standard dose is from about 7 to about 30 mg/kg/day IV or about 7 to about 50 mg/kg/day one to four times daily by mouth.
  • the dose can be administered as a single injection or, more typically, by divided doses (usually three or four times daily).
  • the patient In treating SAH the patient should be treated with from about 6 mg/kg/day to about 20 mg/kg/day, preferably from about 10 to about 15 mg/kg/day.
  • the patient In treating mild and moderate to severe head injury the patient should be treated with from about 5 mg/kg/day to about 50 mg/kg/day, preferably from about 10 to about 25 mg/kg/day.
  • the patient In treating ischemic (thromboembolic) stroke the patient should be treated with an initial dose of from about 10 to about 25 mg/kg on day one, preferably from about 12.5 mg (males) and 15 mg (females) to about 20 mg/kg, to be followed by about 10 mg (males) and about 12.5 mg/kg (females) to about 20 mg/kg for about 3 days.
  • an initial dose of from about 10 to about 25 mg/kg on day one, preferably from about 12.5 mg (males) and 15 mg (females) to about 20 mg/kg, to be followed by about 10 mg (males) and about 12.5 mg/kg (females) to about 20 mg/kg for about 3 days.
  • the patient is treated with about 5 to about 20 mg/kg/day for one to a few days. It is preferable to treat those with spinal cord injury with about 10 to about 20 mg/kg/day for one day.
  • a steroid such as methylprednisolone sodium succinate prior to the administration of the pyrimido[4,5-b]indoles (I) and the lactams (XIII).
  • Typical treatment may involve an initial loading dose, e.g. an IV dose of 0.05 mg to 4 mg/kg followed by maintenance dosing usually given four times a day by IV bolus infusion for one to 10 days depending on the particular condition of the patient and the particular compound used. This may be supplemented with IM or oral dosing for days, weeks or months.
  • the preferred use of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) is to treat inflammatory lung maladies such as asthma.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are administered orally, IV and by inhalation in the standard dose. It is preferred that the pyrimido[4,5-b]indoles (I) and the lactams (XIII) be administered either orally or by aerosol.
  • oral doses are about 5 to about 40 mg/kg/day given one to four times daily.
  • the oral dose of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are from about 5 to about 30 mg/kg/day.
  • the frequency of administration is one thru 4 times daily.
  • the oral administration of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) to treat excess mucous secretions may go on for months or even years.
  • the susceptible individuals can be pre-treated a few hours before an expected problem.
  • the IV dose is about 5 to about 20 mg/kg/day.
  • the aerosol formulation contains about 0.01 to about 1.0% of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are administered or used about four times daily as needed.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are administered orally using a dose of about 5 to about 30 mg/kg/day, administered or used one to four times a day.
  • the treatment may go on for years.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are administered orally or IV using a dose of about 1.0 to about 50 mg/kg/day, preferably about 5 to about 20 mg/kg/day.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are preferably given concomitantly with IV adriamycin or the individual is pre-treated with the pyrimido[4,5-b]indoles (I) and the lactams (XIII).
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are used according to the standard conditions.
  • the patient can be pretreated with a single IV or IM dose just prior to and after surgery or orally before and after surgery.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are given in a dose of about 5 to 20 mg/kg/day, administered one to four times daily IV and about 5 to about 30 mg/kg/day orally.
  • Typical treatment would be an initial IV loading dose followed by oral dosing for a few days or more.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are given orally in a dose of about 5 to about 30 mg/kg/day, one to four times daily for months or years.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treatment of premature infants who may be maintained in a high oxygen environment.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) improves morbidity and mortality in these cases which are paretically susceptible to intracranial bleeding and bronchopulmonary dysplasia. In this situation the standard treatment is given either IV or orally.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are given orally in a dose of about 5 to about 30 mg/kg/day, once or the amount can be given two to four times daily in divided doses or applied topically as a cream, ointment or lotion or equivalent dosage form in a concentration of about 0.05 to about 5% as long as needed.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) can be used with steroidal agents.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in the prevention and treatment of stress ulcers and of gastric intolerance caused by drugs such as nonsteroidal anti-inflammatory compounds (NOSAC).
  • Stress ulcers are ulcers that develop after exposure to severe conditions such as trauma, burns, sepsis, extensive surgery, acute illnesses, and the like. Patients in intensive care units are particularly prone to develop stress ulcers. Stress ulcers also include lesions that can lead to upper gastrointestinal bleeding; such bleeding is likely to be prevented by these compounds.
  • NOSAC includes drugs such as ibuprofen, aspirin, indomethacin, naproxen, piroxicam and the like that are usually taken for analgesia, and that are often associated with gastrointestinal intolerance characterized by pain and lesions that may lead to bleeding.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) will be administered preferentially by the oral route either as tablets, capsules or liquids, in doses ranging from about 25 to about 500 mg, two to four times a day.
  • the treatment would be either preventive, i.e., starting before ulcers have formed in patients at risk of developing such lesions, or therapeutic, i.e., once the ulcers have formed.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are given either through a nasogastric tube, or parenterally, i.e., IV or IM.
  • the parenteral doses would range from about 5 to about 100 mg and be administered one to four times a day or by IV.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating trauma, intervertebral diseases (slipped disk), traumatic shock, flea bite and other allergies.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating endotoxic or septic shock which follows colic, pretreatment before surgery for colic and treatment of Founder (laminitis).
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) can reduce muscle damage that is a common occurrence during surgical procedures that require that the horse be prone for long periods during surgery.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating acute coliform mastitis, bovine mastitis, acute allergic reaction to feed lot vaccination and shipping fever.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) are useful in treating porcine stress syndrome and thermal stress syndrome.
  • treatment or treating as used in this patent is used broadly and includes both treatment of an existing condition as well as preventing the same condition from occurring where such is possible as is well known to those skilled in the art.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) can be used to treat existing asthma conditions and to prevent future ones from occurring.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) treats spinal trauma and prevent rejection of skin grafts.
  • the pyrimido[4,5-b]indoles (I) and the lactams (XIII) can be used with each other and/or can be used with other pharmaceutical agents in treatment of the conditions listed above as is known to those skilled in the art.
  • an inhibitor of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) metabolism such as ketoconazole or TAO (triacetyloleandomycin) prior to or concurrently with the pyrimido[4,5-b]indoles (I) and the lactams (XIII) administration to raise the blood level of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) and/or certain of its metabolites.
  • ketoconazole should be administered in an amount of about 50 to about 300 mg/day, preferably about 200 mg/day about 1 to about 2 hr for acute uses and about 1 to about 3 hr for repeat dose situations.
  • the exact dosage and frequency of administration of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) depends on the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the pyrimido[4,5-b]indoles (I) and the lactams (XIII) (or biologically active metabolite thereof) in the patient's blood and/or the patient's response to the particular condition being treated.
  • variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed in parenthesis.
  • R i and R j are bonded to the preceding carbon atom.
  • C i is the integer corresponding to the carbon atom number.
  • Cg represents the 6 position or carbon atom number in the steroid nucleus as traditionally designated by those skilled in the art of steroid chemistry.
  • R 6 represents a variable substituent (either monovalent or bivalent) at the C 6 position.
  • cyclic molecular fragment, 4-(ethyl)-1-piperazinyl can be represented by -N * -(CH 2 ) 2 -N(C 2 H 5 )-CH 2 -C * H 2 .
  • a rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic compound.
  • the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial.
  • the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the plane (axial), one substituent is always above the other.
  • variable substituents When a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable.
  • R i When a bivalent variable, R i , is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form " ⁇ -R i-j :ß-R i-k " or some variant thereof. In such a case both ⁇ -R i-j and ß-R i-k are attached to the carbon atom to give
  • the two monovalent variable substituents are ⁇ -R 6-1 -ß-R 6-2 , .... ⁇ -R 6-9 :ß-R 6-10 , etc, giving -C( ⁇ -R 6-1 )(ß-R 6-2 )-, .... -C( ⁇ -R 6-9 ß-R 6-10 )-, etc.
  • bivalent variable may be defined as two separate monovalent variable substituents
  • two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable.
  • R i and R j may be defined to be taken together to form (1) a second bond between C 1 and C 2 or (2) a bivalent group such as oxa (-O-) and the formula thereby describes an epoxide.
  • the carbon atom content of variable substituents is indicated in one of two ways.
  • the first method uses a prefix to the entire name of the variable such as "C 1 -C 4 ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable.
  • the prefix is separated from the variable by a space.
  • C 1 -C 4 alkyl represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given).
  • the prefix indicates the entire carbon atom content of the variable being defined.
  • alkoxycarbonyl describes a group CH 3 -(CH 2 ) n -O-CO- where n is zero, one or two.
  • the carbon atom content of only each portion of the definition is indicated separately by enclosing the "C i -C j " designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined.
  • C 1 -C 3 )alkoxycarbonyl has the same meaning as C 2 -C 4 alkoxycarbonyl because the "C 1 -C 3 " refers only to the carbon atom content of the alkoxy group.
  • (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
  • TLC refers to thin-layer chromatography
  • THF refers to tetrahydrofuran
  • DMSO dimethylsulfoxide
  • DMF refers to dimethylformamide.
  • DDQ refers to 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.
  • Saline refers to an aqueous saturated sodium chloride solution.
  • Chromatography (column and flash chromatography) refers to
  • NMR nuclear (proton) magnetic resonance spectroscopy
  • TMS refers to trimethylsilyl
  • - ⁇ refers to phenyl (C 6 H 5 ).
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit.
  • [M + H] + refers to the positive ion of a parent plus a hydrogen atom.
  • El refers to electron impact.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • the ratios of solvents used are volume/volume (v/v).
  • a mixture of 21.7 g of t-butylamine in 100 mL of tetrahydrofuran is cooled to about -40° and treated over about 15 min with 170 mL of 1.6M n-butyllithium in hexane.
  • the mixture is warmed to 0° for 2 hr, then recooled to -40° and treated over 30 min with a mixture of 25 g of 4-chloro-2, 6-di-1-pyrrolidinylpyrimidine and 50 mL of tetrahydrofuran.
  • the mixture is allowed to warm to 20-25° and is stirred for 16-18 hr. Water (50 mL) is then added and the mixture is concentrated under reduced pressure.
  • lactams (XIII) of the invention are useful as pharmaceutical agents for a number of different indications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Les pyrimido[4,5-b]indoles (I) et les lactames (XIII) décrits dans la présente invention sont des agents pharmaceutiques utiles pour un certain nombre d'indications différentes.
PCT/US1996/002397 1995-03-02 1996-03-01 PYRIMIDO[4,5-b]INDOLES WO1996026941A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US08/875,466 US5795986A (en) 1995-03-02 1996-03-01 Pyrimido 4,5-B!indoles
AU51722/96A AU694853B2 (en) 1995-03-02 1996-03-01 Pyrimido{4,5-b}indoles
NZ304519A NZ304519A (en) 1995-03-02 1996-03-01 Pydrimido[4,5-b]indoles
EP96908500A EP0812322A1 (fr) 1995-03-02 1996-03-01 PYRIMIDO 4,5-b]INDOLES
JP8526336A JPH11501623A (ja) 1995-03-02 1996-03-01 ピリミド［４，５−ｂ］インドール
MXPA/A/1997/006632A MXPA97006632A (en) 1995-03-02 1997-09-02 Pirimido [4,5-b] indo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39820195A 1995-03-02 1995-03-02
US08/398,201 1995-03-02

Publications (1)

Publication Number Publication Date
WO1996026941A1 true WO1996026941A1 (fr) 1996-09-06

Family

ID=23574405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002397 WO1996026941A1 (fr) 1995-03-02 1996-03-01 PYRIMIDO[4,5-b]INDOLES

Country Status (9)

Country Link
US (1) US5795986A (fr)
EP (1) EP0812322A1 (fr)
JP (1) JPH11501623A (fr)
KR (1) KR19980702716A (fr)
CN (1) CN1177354A (fr)
AU (1) AU694853B2 (fr)
CA (1) CA2212195A1 (fr)
NZ (1) NZ304519A (fr)
WO (1) WO1996026941A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042708A2 (fr) * 1997-01-08 1998-10-01 Pharmacia & Upjohn Company Amines tricycliques pharmaceutiquement actives
WO2003037898A1 (fr) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Derives de pyrimido [4,5-b] indole
WO2006111648A1 (fr) 2005-04-20 2006-10-26 Sanofi-Aventis DÉRIVÉS DE 1 H-PYRIMIDO[4,5-b]INDOLE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
FR2918665A1 (fr) * 2007-07-13 2009-01-16 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25
FR2945530A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
WO2010130900A3 (fr) * 2009-05-15 2011-04-07 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
US9732083B2 (en) 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514540A1 (fr) * 1989-09-19 1992-11-25 Teijin Limited DERIVE DE PYRROLO 2,3-d]PYRIMIDINE, SON PROCEDE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE COMPRENANT LE DERIVE COMME INGREDIENT ACTIF
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514540A1 (fr) * 1989-09-19 1992-11-25 Teijin Limited DERIVE DE PYRROLO 2,3-d]PYRIMIDINE, SON PROCEDE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE COMPRENANT LE DERIVE COMME INGREDIENT ACTIF
WO1993020078A1 (fr) * 1992-04-03 1993-10-14 The Upjohn Company Amines bicycliques-heterocycliques efficaces pharmaceutiquement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUNDY ET AL: "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity.", J.MED.CHEM., vol. 38, no. 21, 13 October 1995 (1995-10-13), pages 4161 - 4163, XP002006837 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042708A2 (fr) * 1997-01-08 1998-10-01 Pharmacia & Upjohn Company Amines tricycliques pharmaceutiquement actives
WO1998042708A3 (fr) * 1997-01-08 1998-12-17 Upjohn Co Amines tricycliques pharmaceutiquement actives
US5932728A (en) * 1997-01-08 1999-08-03 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
AU723709B2 (en) * 1997-01-08 2000-09-07 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
CN1128798C (zh) * 1997-01-08 2003-11-26 法玛西雅厄普约翰美国公司 具有药物活性的三环胺类
WO2003037898A1 (fr) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Derives de pyrimido [4,5-b] indole
US7547706B2 (en) 2005-04-20 2009-06-16 Sanofi-Aventis 1H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use
FR2884824A1 (fr) * 2005-04-20 2006-10-27 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
WO2006111648A1 (fr) 2005-04-20 2006-10-26 Sanofi-Aventis DÉRIVÉS DE 1 H-PYRIMIDO[4,5-b]INDOLE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
WO2008152223A1 (fr) * 2007-05-04 2008-12-18 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
FR2918665A1 (fr) * 2007-07-13 2009-01-16 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25
WO2009034258A1 (fr) * 2007-07-13 2009-03-19 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25
FR2945530A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
WO2010130900A3 (fr) * 2009-05-15 2011-04-07 Ipsen Pharma S.A.S. Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
US9732083B2 (en) 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
US10858360B2 (en) 2011-03-15 2020-12-08 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors

Also Published As

Publication number Publication date
KR19980702716A (ko) 1998-08-05
JPH11501623A (ja) 1999-02-09
AU5172296A (en) 1996-09-18
CA2212195A1 (fr) 1996-09-06
MX9706632A (es) 1997-11-29
NZ304519A (en) 2000-01-28
EP0812322A1 (fr) 1997-12-17
US5795986A (en) 1998-08-18
AU694853B2 (en) 1998-07-30
CN1177354A (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
EP0633886B1 (fr) Amines bicycliques-heterocycliques efficaces pharmaceutiquement
JP4276376B2 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
US5502187A (en) Pharmaceutically active bicyclic-heterocyclic amines
US4996318A (en) Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke
PT93823B (pt) Processo para a preparacao de derivados de pirimidina e de composicoes farmaceuticas que os contem
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
JPH10512896A (ja) アリールおよびヘテロアリールプリン化合物
JP2003533453A (ja) ホスホジエステラーゼ阻害剤として有効なβ−カルボリン誘導体
TW201100083A (en) Novel pyrimidine derivatives and their use in the treatment of disease
EA025568B1 (ru) Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
WO2017000379A1 (fr) Complexe de silicium et de phthalocyanine, et procédé de préparation et application pharmaceutique de ce dernier
US5795986A (en) Pyrimido 4,5-B!indoles
JP4564713B2 (ja) 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
WO2018086242A1 (fr) Complexe de phtalocyanine de silicium à substitution axiale sensible au ph, son procédé de préparation et son application médicale
RU2200737C2 (ru) Пиримидо[4,5-b]индолы и промежуточное соединение (варианты)
WO2020160054A1 (fr) Dérivés d'imidazoquinoline amine, composition pharmaceutique, utilisation de ceux-ci
US10906915B2 (en) Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
KR101165483B1 (ko) 2Ｈ- 또는 3Ｈ-벤조［ｅ］인다졸-1-일 카르바메이트 유도체, 이들의 제조 방법 및 치료 용도
AU642711B2 (en) 5-oxygenated-2,4,6-triaminopyrimidines
EP0785191B1 (fr) Derives de fusion de l'indane et leurs sels
CN116239603A (zh) 一种2-氨基嘧啶杂环类化合物及其应用
MXPA97006632A (en) Pirimido [4,5-b] indo
CN116283764A (zh) 硝羟喹啉前药及其制备方法和用途
WO2024109942A1 (fr) Inhibiteur de pkmyt1, son procédé de préparation et composition pharmaceutique et son utilisation
IE902437A1 (en) 6- and 7-Deoxyforskolin and derivatives thereof,¹intermediates and a process for their preparation and their¹use as medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192316.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08875466

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2212195

Country of ref document: CA

Ref document number: 2212195

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1996 526336

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019970706123

Country of ref document: KR

Ref document number: 304519

Country of ref document: NZ

Ref document number: PA/a/1997/006632

Country of ref document: MX

Ref document number: 1996908500

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996908500

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970706123

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996908500

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970706123

Country of ref document: KR